Top 10 Early Stage Investors in Cancer Therapeutics & Diagnostics
| Rank | Investor Name |
|---|---|
| 1 | Even One Ventures |
| 2 | dRx Capital |
| 3 | Camden Partners |
| 4 | Astellas Venture Management |
| 5 | Cormorant Asset Management |
| 6 | F-Prime Capital |
| 7 | Eli Lilly and Company |
| 8 | Frazier Healthcare Partners |
| 9 | New Enterprise Associates |
| 10 | RA Capital Management |
Early stage activity in this category is led by institutional venture franchises and category specialists. Oncology remains the deepest therapeutic category, driven by precision medicine and strategic pharma demand. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.